SOURCE: INSYS Therapeutics

Insys Therapeutics

January 06, 2014 17:18 ET

Insys Therapeutics to Present at the 32nd Annual J.P. Morgan Healthcare Conference

PHOENIX, AZ--(Marketwired - Jan 6, 2014) - Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that the Company will present at the 32nd Annual J.P. Morgan Healthcare Conference to be held January 13-16, 2014 at the Westin St. Francis Hotel in San Francisco.

Michael L. Babich, President and Chief Executive Officer, will host the presentation on Thursday, January 16, 2014 at 1:00 p.m. PST.

During this presentation, material information concerning the Company, its operations, strategies and prospects may be discussed. To listen to the audio webcast of this presentation during the event, please visit: www.insysrx.com. A replay of this webcast will be available for 30 days after the initial presentation.

About Insys Therapeutics, Inc.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products, with a focus on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company has two marketed products including Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients. Insys markets Subsys through its incentive-based, cost-efficient commercial sales force. The company's lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol, which would be its second branded supportive care product, if approved.

Contact Information

  • Contact:
    Lisa M. Wilson
    President
    In-Site Communications, Inc.
    212-452-2793